Bellwether Wuxi Biologics' Plunge Indicative Of China Biotech Challenges
Forecasts Hauled Back
Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.
